About PAVBLU

PAVBLU is a prescription medication containing the active ingredient Aflibercept, a recombinant fusion protein that inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). It is used to treat certain types of cancer, including colorectal cancer, non-small cell lung cancer, and breast cancer.

Key Benefits & Uses

Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy
Treatment of non-small cell lung cancer in combination with carboplatin and paclitaxel
Treatment of breast cancer in combination with paclitaxel

Active Ingredient & Action

Aflibercept works by binding to VEGF and PlGF, which are proteins that promote the growth of new blood vessels. By inhibiting the action of these proteins, Aflibercept reduces the formation of new blood vessels that feed tumors, thereby slowing down tumor growth and reducing the risk of cancer progression.

Important Notes

PAVBLU is a prescription medication and should only be used under the guidance of a qualified healthcare professional. It is essential to follow the recommended dosage and administration instructions carefully to minimize the risk of adverse effects. Common side effects of PAVBLU may include hypertension, proteinuria, and headache. Patients with a history of hypertension or proteinuria should be closely monitored while receiving PAVBLU treatment.